Skip to main content
Premium Trial:

Request an Annual Quote

Pangea Raises Additional $4M in Private Financing

Premium

OAKLAND, Calif.--After raising $15 million in an initial round of Series C financing that was completed in December, privately held bioinformatics company Pangea Systems announced last month that it has raised an additional $4 million. Pangea CEO John Couch said the new investors, Burrill Agbio Capital Fund and Mitsui, bring unique experience in the agbio field and Japanese markets. Burrill invests in companies with broadly applicable technology platforms that have commercial importance in agricultural biotechnology and human health care. Mitsui invests in early-stage information technology and healthcare companies. "Their expertise positions us nicely to grow into new areas," Couch said.

The initial round included MDS Capital, Boston Millennia Partners, Institutional Venture Partners, Mayfield Fund, Kleiner Perkins Caufield and Byers, Levensohn Capital Management, and Moss Forest Ventures.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.